The Food & Drug Administration (FDA) has advised women with breast implants to get periodic breast cancer screenings in an effort to detect the disease early.
The new guidelines echo a 2011 warning about a potential risk for implant recipients for the development of anaplastic large-cell lymphoma, according to an announcement from the American Cancer Society.
During the past six years, a bevy of sources, from patients to scientific journals, have verified the link exists, according to the announcement.
The World Health Organization recognized the link between implants and anaplastic large-cell lymphoma last year, according to the announcement. This type of cancer occurs more often in women whose implants have a textured surface compared to smooth surfaces.
The FDA provided two guidelines for specific patient scenarios. First, breast implant candidates should discuss potential side effects of different implant devices. Second, periodic checkups and self-exams should be maintained. Discomfort, inflammation and other symptoms warrant medical attention, the release stated.
